We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Fecal Analyses Leads to Inflammatory Bowel Disease Diagnosis

By LabMedica International staff writers
Posted on 23 Feb 2016
The development of sophisticated analytical techniques has enabled the study and interpretation of changes in the fecal volatile organic metabolites and its correlation with the pathophysiological mechanisms in the gut during health and disease.

The etiology of inflammatory bowel disease (IBD) remains poorly understood, but recent evidence suggests an important role of gut microbial dysbiosis (also called dysbacteriosis, a term for a microbial imbalance on or inside the body) in IBD, and this may be associated with changes in fecal volatile organic metabolites (VOMs).

Gastroenterologists at the University Hospital Southampton (UK) and their colleagues obtained fecal samples from 117 people with Crohn's disease (CD), 100 with ulcerative colitis (UC), and 109 healthy controls. More...
Fecal VOMs were extracted using solid-phase micro-extraction and analyzed by gas chromatography mass spectrometry. Data analysis was carried out using partial least squares-discriminate analysis (PLS-DA) to determine class membership based on distinct metabolomic profiles.

Fecal samples were submitted within six hours of bowel movement. A 2-gram aliquot was placed into 18-mL headspace vial (Supelco; Poole, UK). The VOMs were thermally desorbed by immediately transferring the fiber into the heated injection port (220 °C) of a Clarus 500 gas chromatography mass spectrometry (GC-MS, PerkinElmer; Beaconsfield, UK). The GC-MS generated a chromatogram with peaks representing individual compounds.

The scientists used the PLS-DA model to show clear separation of active CD from inactive disease and healthy controls. Heptanal, 1-octen-3-ol, 2-piperidinone and 6-methyl-2-heptanone were up-regulated in the active CD group [variable importance in projection (VIP) score 2.8, 2.7, 2.6 and 2.4, respectively], while methanethiol, 3-methyl-phenol, short-chain fatty acids and ester derivatives were found to be less abundant (VIP score of 3.5, 2.6, 1.5 and 1.2, respectively). The PLS-DA model also separated patients with small bowel CD from healthy controls and those with colonic CD from UC. In contrast, less distinct separation was observed between active UC, inactive UC and healthy controls.

The authors concluded that analysis of fecal volatile organic metabolites can provide an understanding of gut metabolomic changes in IBD. It has the potential to provide a noninvasive means of diagnosing IBD, and can differentiate between UC and CD. New studies indicates that analyses of vapors from fecal samples can identify volatile metabolites indicative of different types of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. The study was published online on January 25, 2016, in the journal Alimentary Pharmacology & Therapeutics.

Related Links:

University Hospital Southampton
Supelco
PerkinElmer 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.